2017
DOI: 10.1016/j.rdc.2016.12.002
|View full text |Cite
|
Sign up to set email alerts
|

Lactation and Management of Postpartum Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 90 publications
0
9
0
1
Order By: Relevance
“…Our results agree with Fayez et al who reported that increased level of serum prolactin was found in patients with high disease activity when compared to moderate and low disease activity and serum prolactin level was significantly correlated with DAS28 and ESR [20], also, Fojtíková et al reported that RA patients with active disease had high serum prolactin level which correlated significantly with disease activity and Larsen score [35]. Many previous studies have explored the effect of breastfeeding on disease activity during the postpartum period which is challenging for women suffering from rheumatologic diseases due to the increased risk of disease flare and limitations in the use of medications during breastfeeding [36]. Barrett et al found that breastfeeding women with inflammatory polyarthritis developed a more aggressive disease 6 months later in comparison to previous breastfeeders and nonbreastfeeders [16].…”
Section: Discussionmentioning
confidence: 99%
“…Our results agree with Fayez et al who reported that increased level of serum prolactin was found in patients with high disease activity when compared to moderate and low disease activity and serum prolactin level was significantly correlated with DAS28 and ESR [20], also, Fojtíková et al reported that RA patients with active disease had high serum prolactin level which correlated significantly with disease activity and Larsen score [35]. Many previous studies have explored the effect of breastfeeding on disease activity during the postpartum period which is challenging for women suffering from rheumatologic diseases due to the increased risk of disease flare and limitations in the use of medications during breastfeeding [36]. Barrett et al found that breastfeeding women with inflammatory polyarthritis developed a more aggressive disease 6 months later in comparison to previous breastfeeders and nonbreastfeeders [16].…”
Section: Discussionmentioning
confidence: 99%
“…A clear pattern of malformations has been identified through evaluations of pregnant women exposed to MTX [ 82 84 ]. Although less than 10% of MTX consumed is excreted into breast milk [ 85 ], these small amounts can result in immunosuppression of the infant [ 82 ]; therefore, nursing is not recommended for mothers being treated with MTX [ 57 , 86 ].…”
Section: Immunosuppressive and Immomodulating Agents Used In The Treamentioning
confidence: 99%
“…Janus kinase (JAK) inhibitors are oral biologic agents used to treat rheumatoid arthritis. JAK inhibitors such as tofacitinib have a lower molecular weight thus implying a risk for transfer into the breast milk [23,24].…”
Section: Breastfeedingmentioning
confidence: 99%
-